Orgenesis (NASDAQ:ORGS – Get Rating) and Amarin (NASDAQ:AMRN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.
Earnings & Valuation
This table compares Orgenesis and Amarin’s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Orgenesis | $35.50 million | 1.45 | -$18.05 million | $0.32 | 6.47 |
Amarin | $583.19 million | 0.97 | $7.73 million | ($0.05) | -28.39 |
Amarin has higher revenue and earnings than Orgenesis. Amarin is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and target prices for Orgenesis and Amarin, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Orgenesis | 0 | 0 | 0 | 0 | N/A |
Amarin | 1 | 3 | 1 | 0 | 2.00 |
Amarin has a consensus price target of $5.33, indicating a potential upside of 275.59%. Given Amarin’s higher probable upside, analysts clearly believe Amarin is more favorable than Orgenesis.
Insider & Institutional Ownership
15.2% of Orgenesis shares are held by institutional investors. Comparatively, 35.4% of Amarin shares are held by institutional investors. 7.7% of Orgenesis shares are held by company insiders. Comparatively, 2.7% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Orgenesis and Amarin’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Orgenesis | 22.02% | 16.12% | 10.73% |
Amarin | -4.15% | -1.31% | -0.82% |
Volatility and Risk
Orgenesis has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Amarin has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Summary
Orgenesis beats Amarin on 7 of the 13 factors compared between the two stocks.
About Orgenesis (Get Rating)
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
About Amarin (Get Rating)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Orgenesis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Orgenesis and related companies with MarketBeat.com’s FREE daily email newsletter.
Read More: Head to Head Review: Orgenesis (NASDAQ:ORGS) versus Amarin (NASDAQ:AMRN)